Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ctxt Pty Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are assigned to 2 distinct examiners, providing different reviewers for each matter. Despite having multiple examiners, both pending office actions are located within 1 distinct art unit, suggesting a very specific technical focus. This concentration allows for a more consistent approach to prosecution within the specified art unit.
SHOWALTER, ALEXANDER KEITH is the busiest examiner for the company, with 1 busiest examiner pending action. With 2 pending office actions and 2 distinct examiners, the workload is evenly divided across the portfolio. The concentration of both actions in 1 distinct art unit means that while the examiners are different, they likely follow the same art unit-specific guidelines. The involvement of 2 distinct examiners ensures that the company receives a variety of perspectives on its applications.
This profile indicates a focused prosecution strategy in the Biotechnology & Pharmaceuticals sector. The company manages 2 distinct examiners within 1 distinct art unit for its 2 pending office actions. This structure allows for some variety in examiner interaction while maintaining a consistent administrative environment. Practitioners should focus on the specific standards of the 1 distinct art unit while managing the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOWALTER, ALEXANDER KEITH | 1 | 55.4% | +27.3% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18903849 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | SHOWALTER, ALEXANDER KEITH | — |
| 18016070 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1629 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903849 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18016070 | KAT6 INHIBITOR METHODS AND COMBINATIONS FOR CANCER TREATMENT | FETTEROLF, BRANDON J | 1629 | DP | Final Rejection | — | Pending |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCtxt Pty Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Alexander Keith Showalter has the most, with 1 of Ctxt Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
